Detailed Information on Publication Record
2021
Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks
MIKULKOVA, Zuzana, Gayane MANUKYAN, Peter TURCSANYI, Milos KUDELKA, Renata URBANOVA et. al.Basic information
Original name
Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks
Authors
MIKULKOVA, Zuzana (203 Czech Republic), Gayane MANUKYAN, Peter TURCSANYI, Milos KUDELKA (203 Czech Republic), Renata URBANOVA (203 Czech Republic), Jakub SAVARA (203 Czech Republic), Eliska OCHODKOVA (203 Czech Republic), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Jan MOLINSKY (203 Czech Republic), Martin SIMKOVIC (203 Czech Republic), David STAROSTKA (203 Czech Republic), Jan NOVAK (203 Czech Republic), Ondrej JANCA (203 Czech Republic), Martin DIHEL (203 Czech Republic), Pavlina RYZNEROVA (203 Czech Republic), Lekaa MOHAMMAD, Tomas PAPAJIK (203 Czech Republic) and Eva KRIEGOVA (203 Czech Republic, guarantor)
Edition
Nature Scientific Reports, London, NATURE RESEARCH, 2021, 2045-2322
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
Germany
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.996
RIV identification code
RIV/00216224:14110/21:00121640
Organization unit
Faculty of Medicine
UT WoS
000627829300026
Keywords in English
chronic lymphocytic leukaemia; complex circulating immune cell
Tags
International impact, Reviewed
Změněno: 24/5/2021 14:25, Mgr. Tereza Miškechová
Abstract
V originále
The tissue microenvironment in chronic lymphocytic leukaemia (CLL) plays a key role in the pathogenesis of CLL, but the complex blood microenvironment in CLL has not yet been fully characterised. Therefore, immunophenotyping of circulating immune cells in 244 CLL patients and 52 healthy controls was performed using flow cytometry and analysed by multivariate Patient Similarity Networks (PSNs). Our study revealed high inter-individual heterogeneity in the distribution and activation of bystander immune cells in CLL, depending on the bulk of the CLL cells. High CLL counts were associated with low activation on circulating monocytes and T cells and vice versa. The highest activation of immune cells, particularly of intermediate and non-classical monocytes, was evident in patients treated with novel agents. PSNs revealed a low activation of immune cells in CLL progression, irrespective of IgHV status, Binet stage and TP53 disruption. Patients with high intermediate monocytes (>5.4%) with low activation were 2.5 times more likely (95% confidence interval 1.421-4.403, P=0.002) to had shorter time-to-treatment than those with low monocyte counts. Our study demonstrated the association between the activation of circulating immune cells and the bulk of CLL cells. The highest activation of bystander immune cells was detected in patients with slow disease course and in those treated with novel agents. The subset of intermediate monocytes showed predictive value for time-to-treatment in CLL.